You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting
Intro Teams often fail not because of a lack of data, but because of research that confirms what they already believe. The
Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science
~1.5 years ago I was reading a Financial Times article (FT.com) on obesity drugs and their order to market when my critical
Following last week’s post on the slow activity in M&A in 2025 so far (Sivan-Consulting), we now have some activity picking up,
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense
This post/article is worth a read for those interested in the evolution of Pharma Business models: Pharma Exec – The Teva Turnaround
This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies, based
I recently read an interesting paper from Prof. Alexander Schuhmacher et al. on the impact of M&A and licensing on FDA drug
1. Introduction In this project history, I’ll talk about an example of a proactive company preparing for an event several years away,
If you have decided to do a benchmarking exercise and collected a load of data, including primary research, you’re now probably thinking,
This week’s recommendation is a book I’m in the process of reading through a second time: Storytelling with Data: A Data Visualization
Ever find yourself mid-way through a research consulting project and disagreeing on what can be delivered? It’s the start of the year
With the start of the new year, you may look at your company, business unit, or function and decide it is time
